Skip to main content

Advertisement

Log in

Telmisartan, An Angiotensin II Type 1 Receptor Blocker, Controls Progress of Nonalcoholic Steatohepatitis in Rats

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The term nonalcoholic steatohepatitis (NASH) has recently been proposed to identify a fatty liver disease accompanied by diffuse fatty infiltration and inflammation. However, no drug therapy has been established for NASH as yet. In the present study, we demonstrate the effect of the angiotensin II type 1 receptor antagonist telmisartan on the development of NASH in a rat model. Telmisartan, but not the angiotensin receptor antagonist valsartan, markedly attenuated hepatic steatosis, inflammation, and fibrosis in these rats. The quantitative parameters of steatosis, inflammation, and fibrosis were also ameliorated by treatment with telmisartan. Compared with telmisartan, the peroxisome proliferator-activated receptor-γ agonist pioglitazone attenuated hepatic steatosis and fibrosis of the liver to a similar degree. However, telmisartan, but not pioglitazone, dramatically decreased both subcutaneous and visceral fat. In conclusion, these results indicated that telmisartan should be the drug of first choice for the treatment of patients with NASH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231

    Article  PubMed  CAS  Google Scholar 

  2. Farrell GC (2003) Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 18:124–138

    Article  PubMed  Google Scholar 

  3. Diehl AM, Goodman Z, Ishak KG (1988) Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95:1056–1062

    PubMed  CAS  Google Scholar 

  4. Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434–438

    PubMed  CAS  Google Scholar 

  5. Harrison SA, Kadakia S, Lang KA, Schenker S (2002) Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 97:2714–2724

    PubMed  CAS  Google Scholar 

  6. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74–80

    Article  PubMed  Google Scholar 

  7. Fan JG, Zhong L, Xu ZJ, Tia LY, Ding XD, Li MS, Wang GL (2003) Effects of low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J Gastroenterol 9:2045–2049

    PubMed  Google Scholar 

  8. Miele L, Gabrieli ML, Forgione A, Vero V, Gallo A, Capristo E, Gasbarrini G, Grieco A (2006) Oxidative stress in metabolic syndrome and nonalcoholic steatohepatitis. Is it possible a role for vitamins in clinical practice? Recent Prog Med 97:1–5

    Google Scholar 

  9. Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T, Kintscher U (2006) Regulation of peroxisome proliferator-activated receptor γ activity by losartan metabolites. Hypertension 47:586–589

    Article  PubMed  CAS  Google Scholar 

  10. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW (2006) Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47:1003–1009

    Article  PubMed  CAS  Google Scholar 

  11. Yoshiji H, Kuriyama S, Yoshii J, Fukui H (2001) Angiotensin-α type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34:745–750

    PubMed  CAS  Google Scholar 

  12. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K (2004) Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40:1222–1225

    Article  PubMed  CAS  Google Scholar 

  13. Nakae D (1999) Endogenous liver carcinogenesis in the rat. Pathol Int 49:1028–1042

    Article  PubMed  CAS  Google Scholar 

  14. Sakaida I, Okita K (2006) The role of oxidative stress in NASH and fatty liver model. Hepatol Res 33:128–131

    Article  CAS  Google Scholar 

  15. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K (2004) Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesion in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 315:187–195

    Article  PubMed  CAS  Google Scholar 

  16. Bohm M, Lee M, Kreutz R, Schinke M, Djavidani B, Wagner J, Kaling M, Wienen W, Bader M (1995) Angiotensin II receptor blockade in TGR (mREN2)27: effects of renin- angiotensin-system gene expression and cardiovascular functions. J Hypertens 13:891–899

    Article  PubMed  CAS  Google Scholar 

  17. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF (2004) Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287:1035–1043

    Article  CAS  Google Scholar 

  18. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685

    Article  PubMed  CAS  Google Scholar 

  19. Maniatis T, Fritch EF, Sambrook J (1982) Gel electrophoresis. In: Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp 161–175

  20. Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG (1980) Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 104:205–214

    Article  PubMed  CAS  Google Scholar 

  21. Moshage H, Casini A, Lieber CS (1990) Acetaldehyde selectively stimulates collagen production in cultured rat liver fat-storing cells but not in hepatocytes. Hepatology 12:511–518

    Article  PubMed  CAS  Google Scholar 

  22. Chen Y, Hozawa S, Sawamura S, Sato S, Fukuyama N, Tsuji C, Mine T, Okada Y, Tanino R, Ogushi Y, Nakazawa H (2005) Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. Biochem Biophys Res Commun 326:45–51

    Article  PubMed  CAS  Google Scholar 

  23. Niu XL, Yang X, Hoshiai K, Tanaka K, Sawamura S, Koga Y, Nakazawa H (2001) Inducible nitric oxide synthase deficiency does not affect the susceptibility of mice to atherosclerosis but increases collagen content in lesions. Circulation 103:1115–1120

    PubMed  CAS  Google Scholar 

  24. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA (1994) Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107:1103–1109

    PubMed  CAS  Google Scholar 

  25. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74–80

    Article  PubMed  Google Scholar 

  26. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S, Katsukawa F, Hirose H, Shimada A, Watanabe K, Saruta T (1999) Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48:1102–1107

    Article  PubMed  CAS  Google Scholar 

  27. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA (2005) Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 288:E930–934

    Article  PubMed  CAS  Google Scholar 

  28. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Horikoshi H, Yazaki Y, Kadowaki T (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354–1361

    Article  PubMed  CAS  Google Scholar 

  29. Kurtz TW, Pravenec M (2004) Antidiabetic mechanisms of angiotensin -converting enzyme inhibitors and angiotensinα receptor antagonists: beyond the renin-angiotensin system. J Hypertens 22:2253–2261

    Article  PubMed  CAS  Google Scholar 

  30. Pershadsingh HA, Benson SC, Ho CL, Avery MA, Kurtz TW (2003) Identification of PPAR-γ activators that do not promote fluid retention and edema: implications for treating insulin resistant hypertension and the metabolic syndrome. Proceedings of the Endocrine Society Symposium on Nuclear Receptors in Cardiovascular Disease. Hot Topics in Endocrinology 29–35

  31. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin α receptor antagonist with selective PPAR-γ-modulating activity. Hypertension 43:993–1002

    Article  PubMed  CAS  Google Scholar 

  32. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953–12956

    Article  PubMed  CAS  Google Scholar 

  33. Rosen ED, Spiegelman BM (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731–37734

    Article  PubMed  CAS  Google Scholar 

  34. Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS, Nagai R, Matsuhashi N (2001) Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120:460–469

    Article  PubMed  CAS  Google Scholar 

  35. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435

    Article  PubMed  CAS  Google Scholar 

  36. Picard F, Auwerx J (2002) PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22:167–197

    Article  PubMed  CAS  Google Scholar 

  37. Walczak R, Tontonoz P (2002) PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 43:177–186

    PubMed  CAS  Google Scholar 

  38. Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109:2054–2057

    Article  PubMed  CAS  Google Scholar 

  39. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated receptor γ selective modulator. Mol Endocrinol 17:662–676

    Article  PubMed  CAS  Google Scholar 

  40. Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH (2006) Therapy of NAFLD: Antioxidants and cytoprotective agents. J Clin Gastroenterol 40:51–60

    Google Scholar 

  41. Comar KM, Sterling RK (2006) Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 23:207–215

    Article  PubMed  CAS  Google Scholar 

  42. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6:998–1003

    Article  PubMed  CAS  Google Scholar 

  43. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM (2004) Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun 12:315:699–703

    Article  CAS  Google Scholar 

  44. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N (2006) Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR delta agonist, on development of steatohepatitis in mice fed a methionine-and choline-deficient diet. Eur J Pharmacol 536:182–191

    Article  PubMed  CAS  Google Scholar 

  45. Trappoliere M, Tuccillo C, Federico A, Di Leva A, D’Alessio C, Niosi M, Capasso R, Coppola F, Dauria M, Loguercio C (2005) The treatment of NAFLD. Eur Rev Med Pharmacol Sci 9:299–304

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Supported in part by a Grant-in-aid from the Ministry of Health, Labor and Welfare of Japan to AN, by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan Kiban-B to AN, and by a grant from the National Institute of Biomedical Innovation to AN.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Atsushi Nakajima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujita, K., Yoneda, M., Wada, K. et al. Telmisartan, An Angiotensin II Type 1 Receptor Blocker, Controls Progress of Nonalcoholic Steatohepatitis in Rats. Dig Dis Sci 52, 3455–3464 (2007). https://doi.org/10.1007/s10620-007-9741-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-007-9741-4

Keywords

Navigation